National Cancer Center: Phase 1/2 Study of a New Drug Candidate Compound Discovered for the Treatment of Acute Leukemia Begins

2022.04.14

The National Cancer Center (Chuo-ku, Tokyo; Hitoshi Nakagama, President; hereinafter “NCC”), the Shonai Regional Industry Promotion Center (Headquarters: Tsuruoka City, Yamagata Prefecture; Osamu Minagawa, President; hereinafter “Shonai Regional Industry Promotion Center”) and Dainippon Sumitomo Pharma Co. (Headquarters: Osaka, Japan; President & CEO: Hiroshi Nomura; hereinafter “DSP”) are conducting joint research to select candidate biomarkers and investigate indications for the new drug candidate compound DSP-5336 (development code: “DSP-5336”). DSP-5336 is now being administered to the first patient in DSP’s ongoing Phase 1/2 study of the agent in acute leukemia in Japan and North America.
◆Please refer to the following press release for more information.

◆Release_Acute Leukemia New Drug Candidate Phase 1.2 Study
リリース_急性白血病新薬候補化合物フェーズ1.2試験